

The world's most advanced wearable neurotech for mobility

Cionic is pioneering the future of movement through an advanced system that combines wearable neurotechnology, adaptive AI, and connected care. Anchored by the FDA-cleared Neural Sleeve, Cionic is setting a new standard for mobility solutions today and driving innovations that will transform millions of lives tomorrow.



Mission & Vision

Motivated by his daughter's journey with cerebral palsy, founder and CEO Jeremiah Robison launched Cionic with a mission to superpower movement through wearable neurotechnology. Today, as the category-defining company in this field, Cionic is reimagining how we meet the core human need of mobility and building toward a future where people can move further, faster, and fearlessly – across every limb and every condition.

Company Snapshot

- Founded: 2018
- Founder and CEO: Jeremiah Robison
- Headquarters: San Francisco, CA
- Employees: 31
- Total funding: \$35M
- Contact: media@cionic.com

The Cionic System

The most comprehensive and personalized system for mobility:



The Neural Sleeve 2:

World-class "bionic clothing" design meets groundbreaking technology, with Al-powered smart sensors that measure, stimulate, and adapt in real time to restore mobility and retrain muscle movement.



The Cionic App:

An always-on companion app for measuring progress, personalizing muscle activation, and accessing a growing library of training programs.



Mobility Specialists:

On-demand mobility specialists who support users from day one, and onward.

Milestones

- Opened state-of-the-art manufacturing facility in 2022
- Launched first FDA-cleared Neural Sleeve in 2023
- Launched FDA-cleared Neural Sleeve 2 in 2025
- 2 million hours of real-world wear on thousands of customers
- 500 million steps stimulated
- 1,500 prescribers nationwide
- 35 clinical, research, and advocacy partnerships
- 20+ diagnoses supported, including multiple sclerosis, cerebral palsy, spinal cord injury, stroke, and other neurological conditions

Clinical Evidence

- 94% of participants demonstrated improved gait in back-toback paired tests in multi-center research trial 1
 - 68% increase to foot clearance 1
 - 44% improvement to ankle stability ¹
- 30% improvement to spasticity reported by home trial participants using the Neural Sleeve 2 ²

Investors















Awards







Key Partners

- National Multiple Sclerosis Society
- Multiple Sclerosis Association of America
- The University of Washington
- The Shirley Ryan AbilityLab
- Stanford University
- fuseproject